Modulation of CD4 + CD28 null T Lymphocytes by Tumor Necrosis Factor-α Blockade in Patients With Unstable Angina
- 16 May 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 113 (19), 2272-2277
- https://doi.org/10.1161/circulationaha.105.588533
Abstract
Background— Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine that favors the expansion of CD4 + CD28 null T cells, an aggressive and unusual proinflammatory lymphocyte subset frequently observed in patients with unstable angina (UA). The purpose of the present ex vivo study was to evaluate whether inflammation in patients with UA may be modulated by selective blockade of TNF-α. Methods and Results— Peripheral blood samples were collected from 17 patients with UA (Braunwald’s class IIIB). CD4 + CD28 null T cells were assessed by flow cytometry and expressed as a percentage of all CD4 + T cells after 24 hours of incubation of whole blood with and without increasing doses (0.1, 1, 10, and 100 μg/mL) of infliximab, an anti–TNF-α monoclonal antibody. In addition, CD28 expression was assessed and expressed as mean fluorescence intensity (geometric mean of the CD28 fluorescence value on all CD4 + T cells). CD4 + CD28 null T-cell percentage decreased from a median of 6.2% (range, 1.2% to 23.9%) to 4.9% (range, 1.1% to 21.9%), 4.5% (range, 1.1% to 21.6%), and 4.1% (range, 0.4% to 21.4%) after incubation with 1, 10, and 100 μg/mL of infliximab ( P for trend=0.043). Analysis of CD28 mean fluorescence intensity showed that the expression of CD28 on cell surface significantly increased after incubation with increasing doses of infliximab ( P for trend=0.03). Conclusions— The findings of this ex vivo study show that CD4 + CD28 null T-cell expansion in patients with UA may be reduced by selective TNF-α blockade. Further studies are warranted to evaluate the clinical benefit of CD4 + CD28 null T-cell modulation.Keywords
This publication has 26 references indexed in Scilit:
- Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritisArthritis & Rheumatism, 2005
- Immune Activation in Chronic Heart FailureThe American Journal of Cardiology, 2005
- Heat-Shock Protein 60-Reactive CD4+CD28nullT Cells in Patients With Acute Coronary SyndromesCirculation, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Unusual Form of Truncus Arteriosus Associated With 22q11 DeletionCirculation, 2002
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarctionJournal of the American College of Cardiology, 1990
- Increased subendothelial infiltration of the coronary arteries with monocytes/macrophages in patients with unstable angina Histological data on 14 autopsied patientsAtherosclerosis, 1987